Sporos News

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

SPR1 Demonstrates Single Agent Anti-Tumor Activity in vivo, Achieving Regression in Established, Large Volume Tumors SPR1 Synergizes with MAPK Inhibitors and Upstream Activators of the MAPK Pathway HOUSTON, Texas., October 26, 2022 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline …

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium Read More »

Sporos Bioventures Announces Formation of Strategic Advisory Board

Dr. Doug Williams to Chair SAB Inaugural members include Drs. Keith Flaherty, Bing Yao, and Doug Hanahan to advise on company’s growing pipeline and discovery engine HOUSTON, Texas., January 11, 2022 — Sporos Bioventures, LLC, (“Sporos” or the “Company”) a private biotechnology company catalyzing the rapid development of potential breakthrough therapies that target novel disease …

Sporos Bioventures Announces Formation of Strategic Advisory Board Read More »

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

HOUSTON–(BUSINESS WIRE)– Sporos Bioventures, LLC (“Sporos” or the “Company”), a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in oncology and immune-related diseases, today announced the appointment of Rachel Humphrey, M.D. to its Board of Directors. “We are thrilled to welcome Rachel to …

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors Read More »

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

HOUSTON, Texas., September 29, 2021 — Sporos Bioventures, LLC, a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases, today announced the appointment of Amit Rakhit, M.D., M.B.A. as chief executive officer. Dr. Rakhit joins Sporos from …

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer Read More »

Sporos Launches with $38.1 Million Series A Financing

Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities Leadership team includes founding chief financial officer Michael Wyzga, formerly of Genzyme HOUSTON, Texas., May 6, 2021— Sporos Bioventures, LLC (the “Company” or “Sporos”), officially launched today with the close of a $38.1 million Series …

Sporos Launches with $38.1 Million Series A Financing Read More »

Scroll to Top